profile-img
NEJM

@NEJM

The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.

calendar_today23-03-2009 04:10:07

28,4K Tweets

931,7K Followers

418 Following

NEJM(@NEJM) 's Twitter Profile Photo
NEJM
@NEJM

1 year ago

In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. nej.md/3Nol806

In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk nej.md/3Nol806
account_circle